Copyright © Inderes 2011 - present. All rights reserved.

Faron Pharmaceuticals

2.02

 

EUR

 

-0.74 %

Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

5,008 following
Compare
-0.74%
+13.1%
-22.31%
+72.06%
-46.42%
-47.12%
-38.97%
-34.84%
-41.95%

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
211.34M EUR
Turnover
87.7K EUR
P/E (adj.) (24e)
-7.11
EV/EBIT (adj.) (24e)
-8.25
P/B (24e)
-20.68
EV/S (24e)
53,876.24
Dividend yield-% (24e)
-
Coverage
Recommendation
Accumulate
Target price
2.80 EUR
Updated
11.12.2024
Disclaimer
Latest research

Latest analysis report

Released: 11.12.2024

Latest extensive report

Released: 23.08.2022

Financial calendar
27.2
2025

Annual report '24

21.3
2025

General meeting '24

27.8
2025

Interim report Q2'25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Research by
Antti Siltanen

Faron: Towards final read-out in March

Faron reported more detailed interim results of the BEXMAB study at the annual meeting of the American Society of Hematology (ASH). The company is on track for the important final read-out in March, as tolerability and overall response rate have remained at good levels.

Faron Pharmaceuticals
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.